转录基因分析和生物信息学驱动的CRC生物标志物的统计优先级:迈向精确瘤学的一步
Rawdhah M Saleh1, Reham Mansour1, Heba A Almaghrbi1
1Department of Biomedical Sciences, College of Health and Sciences, Qatar University, QU Health, Doha, Qatar.
Gene
|May 26, 2025
概括
这项研究确定了五个关键基因 (CDH3,CXCL1,MMP1,MMP3和TGFBI) 作为结直肠腺癌 (COAD) 的潜在生物标志物. 这些基因对开发新的诊断工具和在癌症治疗中推进精确瘤学的发展充满希望.
科学领域:
- 生物信息学和计算生物学
- 癌症基因组学 癌症基因组学
- 分子瘤学分子瘤学
背景情况:
- 结肠直肠腺癌 (COAD) 是全球癌症死亡的主要原因.
- 识别分子生物标志物对于COAD的早期检测和向治疗至关重要.
- COAD的分子复杂性需要先进的计算方法来发现生物标志物.
研究的目的:
- 开发和应用一个综合生物信息学管道,用于识别COAD中的临床相关生物标志物.
- 系统地优先考虑驱动COAD进展的关键分子参与者.
- 评估已识别的生物标志物的诊断和预后潜力.
主要方法:
- 综合差异性基因表达,蛋白质-蛋白质相互作用网络分析和功能丰富.
- 主要成分分析 (PCA) 和整体生存建模用于生物标志物评估.
- 接收器操作特征 (ROC) 曲线分析和定量PCR (qPCR) 用于验证.
主要成果:
- 五个枢纽基因 (CDH3,CXCL1,MMP1,MMP3,TGFBI) 被确定在COAD中显著上调.
- 这些基因涉及到细胞外矩阵降解,表皮-介质细胞过渡 (EMT) 和瘤入侵.
- 实验验证证了这些基因在结直肠癌细胞系中的上调.
结论:
- 建立了一个可复制的生物信息学框架,用于识别结直肠癌 (CRC) 中可操作的生物标志物.
- 五个优先的枢纽基因具有诊断和预后价值.
- 这些发现支持开发非侵入性分子诊断,并为精确瘤学做出贡献.
相关概念视频
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


